Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Mar 10, 2025
-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 --
-- Advancing four clinical programs for hematologic malignancies and autoimmune diseases --
Read more at globenewswire.com
